Beklo100 ml

Muscle Spasticity in Multiple Sclerosis

Beklo is established (FDA-approved) for the management of spasticity resulting from multiple sclerosis, particularly for relief of flexor spasms, associated pain, clonus, and muscular rigidity.

Spasticity from Spinal Cord Injury or Disease

Beklo is established for the management of spasticity due to spinal cord injuries or spinal cord disease.

Other Spastic Conditions

Beklo may also be used, under medical supervision, for spasticity from other central nervous system causes (such as cerebral palsy) as a guideline-supported or commonly used off-label option, although its efficacy for stroke, cerebral palsy, and Parkinson's disease has not been definitively established in controlled trials.

Not Indicated For

Beklo is not indicated for the treatment of skeletal muscle spasm resulting from rheumatic disorders (e.g., simple back strain); other agents are preferred for that purpose.

Each tablet contains Baclofen INN as the active pharmaceutical ingredient, most commonly available as 10 mg and 20 mg oral tablets; oral liquid formulations of Baclofen also exist in some markets for patients who cannot swallow tablets.

Beklo is a centrally acting skeletal muscle relaxant and antispastic agent used to reduce the muscle spasticity, spasms, pain, and stiffness that occur in conditions such as multiple sclerosis and spinal cord injury or disease. It acts on GABA-B receptors mainly at the spinal cord level to inhibit reflex activity between nerves and muscles, thereby easing involuntary muscle contraction. Beklo is taken by mouth, usually starting at a low dose that is gradually increased to find the lowest effective amount that controls symptoms with the fewest side effects. Because Beklo is a central nervous system depressant, it commonly causes drowsiness and dizziness, and it must never be stopped abruptly because doing so can trigger serious withdrawal effects, including hallucinations and seizures.

Skeletal Muscle Relaxant (centrally acting) - GABA-B Receptor Agonist

Mechanism: Baclofen is a structural analog of the inhibitory neurotransmitter GABA (gamma-aminobutyric acid) and acts as a selective agonist at GABA-B receptors. It acts primarily within the spinal cord, where it hyperpolarizes afferent nerve terminals and inhibits the release of excitatory neurotransmitters, thereby suppressing both monosynaptic and polysynaptic reflexes. This action reduces the frequency and severity of muscle spasms, clonus, and rigidity without directly acting on the neuromuscular junction or muscle fibers themselves.

Pharmacokinetics: Baclofen is absorbed rapidly and fairly completely from the gastrointestinal tract, though absorption varies between individuals and is dose-dependent. It is only partially metabolized in the liver, with the majority of an oral dose excreted unchanged by the kidneys. Its elimination half-life is approximately 2.5 to 4 hours. Because renal excretion is the primary elimination route, Baclofen can accumulate in patients with reduced kidney function, requiring dose adjustment.

• Take Beklo by mouth exactly as prescribed, at evenly spaced intervals through the day.
• Beklo may be taken with food or milk if it causes stomach upset.
• Swallow tablets with a full glass of water; do not chew or crush unless directed by a pharmacist for a specific formulation.
• Do not increase the dose of Beklo or take it more often than prescribed, even if spasticity symptoms persist; contact the prescribing doctor instead.
• Never stop taking Beklo suddenly on your own; it must be tapered off gradually under medical supervision (see Precautions and Warnings).
• If a dose of Beklo is missed, take it as soon as remembered unless it is close to the next scheduled dose; do not double the dose.

• Alcohol and other CNS depressants (e.g., opioids, benzodiazepines, sedating antihistamines, other muscle relaxants): combining these with Beklo produces additive central nervous system depression, increasing the risk of excessive sedation, dizziness, and respiratory depression.
• Tricyclic antidepressants: concurrent use with Beklo has been reported to cause marked muscle hypotonia (weakness); the combination should be used cautiously and the patient monitored.
• Antihypertensive agents: Beklo can have an additive blood-pressure-lowering effect when combined with antihypertensive drugs, potentially requiring dose adjustment of the blood pressure medication.
• MAO inhibitors: caution is advised, as combined use may increase CNS and blood pressure effects; consult a physician before combining.
• Other drugs affecting the CNS or general anesthetics: Beklo's sedative effects can be potentiated during surgery or with other centrally acting medicines, so anesthesia providers should be informed that a patient is taking Beklo.

Common Side Effects

• Drowsiness and sedation
• Dizziness or lightheadedness
• Muscle weakness or fatigue
• Nausea
• Headache
• Confusion

Less Common but Serious Side Effects (Seek Medical Attention)

• Marked confusion, hallucinations, or unusual behavior
• Seizures, especially in patients with a seizure disorder (see Precautions and Warnings)
• Respiratory depression or difficulty breathing
• Significant drop in blood pressure (hypotension), fainting
• Urinary retention or difficulty urinating
• Signs of withdrawal (agitation, hallucinations, high fever, muscle rigidity) if Beklo is stopped abruptly (see Precautions and Warnings)
• Signs of a severe allergic reaction: rash, itching, swelling of the face/throat, severe dizziness, trouble breathing

Pregnancy

Human data on Beklo use in pregnancy are limited. Beklo has shown teratogenic effects (such as fetal skeletal abnormalities) in animal reproduction studies at doses higher than typical human doses, though it is not established as definitively teratogenic in humans. Beklo should be used during pregnancy only if the potential benefit to the mother clearly justifies the potential risk to the fetus, and only under a physician's guidance. Infants born to mothers taking Beklo late in pregnancy have, in rare reports, shown withdrawal-like symptoms (tremor, jitteriness, seizures) after birth; where possible, the dose is gradually reduced before delivery under medical supervision.

Breastfeeding

Beklo passes into breast milk in small amounts. Because the effects on a nursing infant are not fully established, breastfeeding while taking Beklo should only be undertaken after consulting a physician, who can weigh the benefits of breastfeeding against the potential risk of infant sedation or other effects, and the infant should be monitored for drowsiness or poor feeding if breastfeeding continues.

• Do not stop abruptly (withdrawal risk): abrupt discontinuation of Beklo, especially after prolonged use, can precipitate serious withdrawal reactions including hallucinations, seizures, high fever, rebound spasticity, and (rarely) a life-threatening reaction; Beklo should always be tapered off gradually under medical supervision unless a serious adverse reaction requires urgent discontinuation.
• CNS depression: Beklo commonly causes drowsiness, dizziness, and weakness; patients should not drive, operate machinery, or perform hazardous tasks until they know how Beklo affects them, and should avoid alcohol and other sedating medicines (see Interaction).
• Renal impairment: because Beklo is cleared mainly by the kidneys, patients with reduced kidney function are at higher risk of drug accumulation and toxicity; a lower dose and careful monitoring are needed (see Use in Special Populations).
• Seizure disorders: Beklo may lower the seizure threshold in susceptible patients, and deterioration in seizure control has been reported; patients with epilepsy should be monitored closely, including EEG monitoring where clinically indicated.
• Psychiatric and cognitive effects: confusion, hallucinations, and other psychiatric disturbances can occur, particularly in elderly patients or with higher doses; caution is advised in patients with a history of psychiatric illness.
• Impaired hepatic or cardiovascular function: Beklo should be used with caution in patients with these conditions, with periodic monitoring of liver function where relevant.

Signs of Beklo overdose can include vomiting, marked muscle weakness (hypotonia), drowsiness progressing to unresponsiveness, difficulty breathing or respiratory depression, seizures, and slowed heart rate. An overdose of Beklo is a medical emergency. If overdose is suspected, seek immediate emergency medical attention or contact a poison control center right away; do not attempt to manage a suspected overdose at home. Treatment is supportive and provided in a medical facility, and may include airway support and close monitoring of breathing and heart function.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

• Renal impairment: Beklo is excreted primarily unchanged by the kidneys; patients with reduced kidney function should receive a lower dose with careful upward titration and monitoring for signs of toxicity (drowsiness, confusion, weakness).
• Hepatic impairment: limited specific data exist; Beklo should be used with caution and liver function monitored where relevant, since a minor portion of the dose is metabolized in the liver.
• Elderly patients: older adults may be more sensitive to the sedative and confusional effects of Beklo; a lower starting dose and slower titration are advisable, with close monitoring.
• Pregnant and breastfeeding women: see Pregnancy and Lactation for detailed guidance.
• Pediatric patients: safety and efficacy of oral Beklo have not been established in children under 12 years; see Pediatric Uses.

The duration of Beklo treatment is individualized based on the underlying cause and severity of spasticity, and is determined by the prescribing physician. Because spasticity from conditions like multiple sclerosis or spinal cord injury/disease is typically a chronic problem, Beklo is often used long-term, with periodic reassessment of its continued benefit and dose. If Beklo does not produce a worthwhile improvement in symptoms within a reasonable trial period (as judged by the physician), it should be gradually withdrawn. Whenever treatment is stopped, the dose must be tapered down gradually rather than discontinued abruptly (see Precautions and Warnings).

Skeletal muscle relaxant; Antispasticity agent; GABA-B receptor agonist

Baclofen is a GABA-B receptor agonist that acts primarily at the spinal cord level. By stimulating GABA-B receptors on afferent nerve terminals, it hyperpolarizes these neurons and inhibits the release of excitatory neurotransmitters, which suppresses monosynaptic and polysynaptic spinal reflexes. This central inhibitory action reduces the frequency and intensity of muscle spasms, clonus, and rigidity associated with spasticity, without acting directly on skeletal muscle fibers or the neuromuscular junction.

C

The safety and efficacy of oral Beklo have not been established in children below 12 years of age for the standard tablet formulation. When Beklo is used in children for spasticity related to cerebral palsy or other central nervous system conditions, this is generally considered an off-label, specialist-guided use, with dosing individualized by a pediatric neurologist or specialist based on the child's age, weight, and response, starting at a low dose and titrating gradually, similar in principle to adult titration but at markedly lower doses. As in adults, Beklo must never be stopped abruptly in a child who has been taking it regularly, because of the risk of withdrawal symptoms; any discontinuation should be gradual and supervised by the treating specialist.